XML 36 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Note 19 - Subsequent Events
6 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Subsequent Events [Text Block]
19.
SUBSEQUENT EVENTS
 
Refer to Note
12
- Convertible Notes Payable for subsequent events related to the notes.
 
On
July 31, 2020,
warrants were exercised for
211,000
shares of common stock.
 
On
August 12, 2020,
warrants were exercised for
475,500
shares of common stock.
 
Underwriting agreement
 
On
July 20, 2020,
the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Maxim Group LLC, as representative of the several underwriters named therein (the “Underwriters”) with respect to the issuance and sale of: (i)
29,130,000
shares (the “Shares”) of common stock,
$0.0001
par value per share (“Common Stock”), (ii) pre-funded warrants to purchase
4,100,000
shares of Common Stock at an exercise price of
$0.01
per share (the “Pre-Funded Warrants”), and (iii) warrants to purchase an aggregate of
33,230,000
shares of Common Stock at an exercise price of
$0.65
per share (the “Common Warrants” and, together with the Pre-Funded Warrants, the “Warrants” and, together with the Shares and the Pre-Funded Warrants, the “Securities”), in an underwritten public offering (the “Offering”) pursuant to the Underwriting Agreement.
 
Each Share was sold together with a Common Warrant to purchase
one
share of Common Stock, at a combined price to the public of
$0.65
per share of Common Stock and accompanying Warrant. Each Pre-Funded Warrant was sold together with a Common Warrant to purchase
one
share of Common Stock, at a combined price to the public of
$0.64
per Pre-Funded Warrant and accompanying Warrant.
 
Each Pre-Funded Warrant is immediately exercisable upon issuance and will expire when exercised in full. The Common Warrants have a term of
five
years and are immediately exercisable. If a registration statement under the Securities Act of
1933,
as amended (the “Securities Act”), registering the issuance of the shares of Common Stock underlying the Common Warrants is
not
effective or available and an exemption from registration under the Securities Act is
not
available for the issuance of such shares, the holders of the Common Warrants
may,
in their sole discretion, elect to exercise their Common Warrants through a cashless exercise. The exercise of the Common Warrants is subject to certain beneficial ownership limitations. The warrants were issued pursuant to the terms of a warrant agency agreement between the Company and Broadridge Issuer Solutions, Inc., as warrant agent.
 
Pursuant to the Underwriting Agreement, the Company granted the Underwriters a
45
-day option to purchase up to an additional
4,984,500
shares of Common Stock and/or
4,984,500
Warrants to cover over-allotments, if any (the “Over-Allotment”). On
July 21, 2020,
the Underwriter exercised its Over-Allotment option in full on both the Common Stock and the Warrants.
 
Pursuant to the Underwriting Agreement, the Company paid the Underwriter a cash fee equal to
8%
of the aggregate gross proceeds sold in the Offering and also agreed to reimburse the Underwriter for reasonable out-of-pocket expenses related to the Offering, including the reasonable fees and expenses of counsel to the Underwriters, in the aggregate maximum amount of up to
$80,000.
 
The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act, other obligations of the parties and termination provisions. The representations, warranties and agreements made by the parties in the Underwriting Agreement were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties, and should
not
be deemed to be a representation, warranty or agreement to or in favor of any party. In addition, the assertions embodied in any representations, warranties and agreements contained in the Underwriting Agreement
may
be subject to qualifications with respect to knowledge and materiality different from those applicable to security holders generally. Moreover, such representations, warranties and agreements should
not
be relied on as accurately representing the current state of the Company's affairs at any time.
 
The Securities were offered by the Company pursuant to an effective registration statement on Form S-
1,
as amended, which was originally filed with the Securities and Exchange Commission on
July 9, 2020,
and was declared effective on
July 20, 2020 (
File
No.
333
-
239782
) (the “Registration Statement”), and registration statement on Form S-
1MEF
(File
No.
333
-
239966
). The Company filed a final prospectus with the SEC on
July 22, 2020
in connection with the sale of the Securities.
  
The Offering and the Over-Allotment option closed on
July 23, 2020.
The net proceeds of the Offering including the full exercise of the Over-Allotment were approximately
$22.8
million, after deducting the underwriting discounts and commissions and estimated offering expenses.  The Company used approximately
$4.2
million of the net proceeds of the Offering to satisfy all outstanding amounts due under convertible promissory notes previously issued.  The prefunded warrants were exercised on
July 23, 2020
and
July 27, 2020
resulting in an increase of common stock of
4,100,000
shares.  Total shares of common stock outstanding increased by
38,214,500
for the underwriting transaction through date of this report.
 
Nasdaq Capital Market listing requirements
 
On
May 18, 2020
the Company received a notice (the “Notice”) from the Staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Capital Market LLC (“Nasdaq”) indicating the Company was
not
in compliance with Nasdaq Listing Rule
5550
(b)(
1
) because, the Company did
not
have a minimum of
$2,500,000
in stockholders' equity for continued listing on Nasdaq (the “Stockholders' Equity Requirement”). On
July 10, 2020,
the Company's  plan to regain compliance with the Stockholders' Equity Requirement previously submitted to the Nasdaq was accepted and Nasdaq granted us an extension of
180
calendar days from the date of the Notice (
November 16, 2020)
for to provide evidence of compliance.
 
As discussed above , on
July 23, 2020,
the Company completed an underwritten public offering resulting in net cash proceeds of approximately
$22.8
million which was used, in part, to repay approximately
$4.2
million of outstanding convertible promissory notes. Accordingly, as of the date of this report the Company believes that it has satisfied compliance with the Stockholders' Equity Requirement and  has been advised that Nasdaq will continue to monitor the Company's ongoing compliance with the Stockholders' Equity Requirement and, if at the time of the Company's next periodic report the Company does
not
evidence compliance, that it
may
be subject to delisting.